Enterprise Value
-12.75M
Cash
103.4M
Avg Qtr Burn
-19.13M
Short % of Float
11.23%
Insider Ownership
4.03%
Institutional Own.
75.50%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BDTX-1535 Details Cancer, Glioblastoma, Non-small cell lung carcinoma | Phase 1 Data readout | |
BDTX-4933 Details Cancer | Phase 1 Initiation | |
BDTX-189 (EGFR HER2) Details Solid tumor/s, Cancer | Failed Discontinued |